Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

80%

8 of 10 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 2
6(60.0%)
Phase 1
2(20.0%)
Phase 3
2(20.0%)
10Total
Phase 2(6)
Phase 1(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT01479127Phase 2Completed

Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

Role: collaborator

NCT00667576Phase 2Completed

Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

Role: collaborator

NCT00445939Phase 2Completed

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Role: collaborator

NCT00603993Phase 3Completed

Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Role: collaborator

NCT00701805Phase 2Completed

Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)

Role: collaborator

NCT00235833Phase 2Completed

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Role: collaborator

NCT00235872Phase 3Completed

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Role: collaborator

NCT00647400Phase 2Completed

Adalimumab in Adult Japanese Subjects With Psoriasis

Role: collaborator

NCT00919490Phase 1Completed

A Study of Single Dose of ABT-333 in Healthy Male Adults

Role: collaborator

NCT01081483Phase 1Completed

A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults

Role: collaborator

All 10 trials loaded